Abstract
While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.
Keywords: dorsal root ganglia, Nrf2 protein, hyperglycemia, oxidative stress, advanced glycation products
Current Drug Targets
Title: The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Volume: 9 Issue: 1
Author(s): Andrea M. Vincent, James L. Edwards, Mahdieh Sadidi and Eva L. Feldman
Affiliation:
Keywords: dorsal root ganglia, Nrf2 protein, hyperglycemia, oxidative stress, advanced glycation products
Abstract: While increasing antioxidant potential is an attractive treatment strategy for diabetic neuropathy, many years of trials using high-dose oral antioxidants have not produced therapeutic results. An increasing understanding of the innate antioxidant response and the pharmacological agents that can regulate this mechanism may open new avenue for drug development. This review describes the current state of antioxidant trials and the potential for targeting the antioxidant response. In combination with antihyperglycemic agents, agents that regulate the antioxidant response may afford superior protection against cellular oxidative injury in diabetes.
Export Options
About this article
Cite this article as:
Vincent M. Andrea, Edwards L. James, Sadidi Mahdieh and Feldman L. Eva, The Antioxidant Response as a Drug Target in Diabetic Neuropathy, Current Drug Targets 2008; 9 (1) . https://dx.doi.org/10.2174/138945008783431754
DOI https://dx.doi.org/10.2174/138945008783431754 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vaccines and Photodynamic Therapies for Oral Microbial-Related Diseases
Current Drug Metabolism Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Is C-Peptide Replacement the Missing Link for Successful Treatment of Neurological Complications in Type 1 Diabetes?
Current Drug Targets Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes
Current Pharmaceutical Design The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Subject Index to Volume 5
Current Drug Targets Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction
Current Pharmaceutical Design Lymphatics and Inflammation
Current Medicinal Chemistry Capsaicin-Sensitive Nociceptive Innervation of the Dura Mater: Implications for the Pathomechanism of Headache
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Redefining the Role of Long-Acting Phosphodiesterase Inhibitor Tadalafil in the Treatment of Diabetic Erectile Dysfunction
Current Diabetes Reviews Painful Peripheral Neuropathies
Current Neuropharmacology Editorial: “Ah, Wherefore with Infection Should he Live?”: Microbial Virulence Factors in Diabetic Foot Ulceration
Current Vascular Pharmacology Cellular Actions of Gabapentin and Related Compounds on Cultured Sensory Neurones
Current Neuropharmacology Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)